We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $69.83, moving +0.34% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.56%. Elsewhere, the Dow gained 1.77%, while the tech-heavy Nasdaq added 2.2%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 11.26% over the past month. This has outpaced the Medical sector's gain of 3.07% and the S&P 500's gain of 6.41% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be February 4, 2019. The company is expected to report EPS of $1.74, down 2.25% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.52 billion, down 7.27% from the prior-year quarter.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% lower. GILD is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, GILD is holding a Forward P/E ratio of 10.11. For comparison, its industry has an average Forward P/E of 22.5, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 58, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $69.83, moving +0.34% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.56%. Elsewhere, the Dow gained 1.77%, while the tech-heavy Nasdaq added 2.2%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 11.26% over the past month. This has outpaced the Medical sector's gain of 3.07% and the S&P 500's gain of 6.41% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be February 4, 2019. The company is expected to report EPS of $1.74, down 2.25% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.52 billion, down 7.27% from the prior-year quarter.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% lower. GILD is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, GILD is holding a Forward P/E ratio of 10.11. For comparison, its industry has an average Forward P/E of 22.5, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 58, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.